BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Debanjana Chatterjee does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 SGMTSagimet Biosciences Inc. Series A Common Stock | Buy | $27.00 | Jun 2025 | +6.7% | Miss |
 TVRDTvardi Therapeutics, Inc. | Buy | $39.00 | Apr 2025 | −91.2% | Hit |
 KALVKalvista Pharmaceuticals Inc | Buy | $30.00 | Mar 2025 | +51.2% | Miss |
 CTNMContineum Therapeutics, Inc. Class A Common Stock | Buy | $23.00 | Mar 2025 | +89.7% | Miss |
| SGMTSagimet Biosciences Inc. Series A Common Stock | Buy | $42.00 | Jan 2025 | +33.3% | Miss |
 PHVSPharvaris BV | Buy | $46.00 | Sep 2024 | +40.1% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.